Recruiting

Testing a new immune therapy for advanced solid cancers

Plain-English translation of NCT05267626 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

This is one of the first times this treatment has been tested in people.

What is this trial?

This study is testing a medication called , a new type of immune therapy designed to help your body fight cancer. Researchers are giving this medication alone or in combination with other approved cancer drugs to people with advanced melanoma or lung cancer. The goal is to see whether this treatment is safe and whether it can slow or stop cancer growth.

Patients with advanced melanoma and lung cancer often run out of treatment options, especially when standard immune therapies stop working. This medication was designed to work through a different mechanism than existing treatments, offering a potential new pathway for patients who have limited options.

Do you qualify?

You likely qualify if…

you have advanced melanoma or non-small cell lung cancer that cannot be surgically removed or has spread to other parts of your body
your cancer has progressed despite receiving at least one standard immune therapy treatment
you have measurable disease that can be seen on CT or MRI scans
you are willing to use effective birth control if you can become pregnant, or if you could father a child
you have not had a recent response to your last cancer treatment (at least 4 weeks of confirmed progression)

You likely don't qualify if…

you are pregnant or breastfeeding
you have certain genetic mutations in your lung cancer (EGFR or ALK) that qualify you for other targeted therapies
you have a positive pregnancy test within 72 hours of starting the study
you are unwilling or unable to use contraception during the study period

What participation looks like

You would receive injections of the medication every two weeks, either alone or combined with other cancer drugs depending on which part of the trial you join. Some participants also receive a single dose of an immune-boosting drug called at the start. You would have regular visits to the study center for blood tests, scans, and check-ups to monitor how the treatment is working and watch for any side effects. The trial is still recruiting participants and is being conducted at multiple medical centers.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Testing a new immune therapy for advanced solid cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations